Nyrada Inc (ASX:NYR) Full Year Results FY21
Highlights: • Research and development costs of $2.2M as Nyrada’s lead preclinical programs advance (FY2020: $1.4M) • Capital raising program… Read more
Highlights: • Research and development costs of $2.2M as Nyrada’s lead preclinical programs advance (FY2020: $1.4M) • Capital raising program… Read more
Last Friday, Nyrada released further positive results from an animal trial using a mouse model genetically modified to mimic human-like… Read more
We wish to draw your attention to an announcement and presentation released by Incannex (ASX:IHL) this week. The company has… Read more
This morning Nyrada announced the granting of a new patent by the US Patent and Trademark Office for their PCSk9i… Read more